An2 Therapeutics (ANTX) closed at $4.35 on November 2, 2026, down 4.0% from the previous close, on volume of 290,277 shares (30-day average 301,975).
Data as of November 2, 2026.
Business Wire (Mon, 2-Nov 7:00 AM ET)
AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)
Business Wire (Fri, 23-Oct 5:00 PM ET)
Business Wire (Wed, 21-Oct 7:00 AM ET)
PRNewswire (Mon, 12-Oct 8:51 AM ET)
AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK
Business Wire (Mon, 28-Sep 7:00 AM ET)
AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)
Business Wire (Wed, 16-Sep 5:33 PM ET)
Business Wire (Mon, 31-Aug 6:00 PM ET)
AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer
Business Wire (Mon, 24-Aug 7:00 AM ET)
Business Wire (Tue, 11-Aug 4:00 PM ET)
ANTX Lands $40 Million Private Placement, Attracting Institutional Backing at $2.85 Per Share
Market Chameleon (Mon, 9-Mar 6:33 AM ET)
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
An2 Therapeutics trades on the NASDAQ stock market under the symbol ANTX.
As of November 3, 2026, ANTX stock price climbed to $4.54 with 1,646 million shares trading.
ANTX has a beta of -0.95, meaning it tends to be less sensitive to market movements. ANTX has a correlation of 0.01 to the broad based SPY ETF.
ANTX has a market cap of $171.32 million. This is considered a Micro Cap stock.
In the last 3 years, ANTX traded as high as $22.22 and as low as $.87.
The top ETF exchange traded funds that ANTX belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.
ANTX has outperformed the market in the last year with a price return of +269.1% while the SPY ETF gained +11.7%. However, in the short term, ANTX had mixed performance relative to the market. It has underperformed in the last 3 months, returning -15.1% vs +1.2% return in SPY. But in the last 2 weeks, ANTX shares have fared better than the market returning +34.7% compared to SPY -1.6%.
ANTX support price is $4.07 and resistance is $4.64 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANTX shares will trade within this expected range on the day.
